News

Emiliem News and Events

January 8, 2010 - Emiliem, Inc. and Jivan Biologics join forces to form JEM Bioscience to discover and commercialize novel molecular diagnostics

January, 2010 - Sucha Sudarsanam, CSO & Dale Johnson, CEO Emiliem, Inc. publish Functional Consequences of mTOR Inhibition in Current Opinion Drug Discovery & Development

October, 2009 - Dale Johnson, CEO Emiliem, Inc. to present Novel Therapeutics Biologics: Innovative Molecules and Mechanisms - MPI Research Summit Augusta, MI

April, 2009 - Dale Johnson, CEO Emiliem, Inc. named to the State of California EPA/DTSC Green Ribbon Science Panel, Sacramento, CA

February, 2009 - Dale Johnson, CEO Emiliem, Inc. to present at Cambridge Healthtech Institute 16th International Molecular Medicine Tri-Conference. Shaping Future Medicine San Francisco, CA

January, 2009 - Dale Johnson, CEO Emiliem, Inc. and co-authors Subha Srinivasan and Jonathan Bingham publish The ABC'S of Human Alternative Splicing: A Review of ATP-binding Cassette Transporter Splicing in Current Opinion Drug Discovery & Development

November, 2008 - Dale Johnson, CEO Emiliem, Inc. to be a panel member at MichBio Biosciences Policy Summit, Novi, MI

September, 2008 - Dale Johnson, CEO Emiliem, Inc. to present Novel Approaches for Anti-angiogenic Therapeutics at Dept. of Pharmaceutical Sciences, University of Michigan in Ann Arbor, MI

October 16, 2007 - Emiliem Creates R&D Center at Southwest Michigan Innovation Center (See press release)

August 28, 2007 - Emiliem and Eidogen-Sertanty Sign Computational Chemistry Master Services Agreement

June 11, 2007 - Emiliem and Kalexsyn Sign Medicinal Chemistry Master Services Agreement

May 21, 2007 - Emiliem featured as an emerging company in BioCentury, The Bernstein Report on BioBusiness

"Emiliem: Not just any kinase".

May 3, 2007 - The Van Andel Research Institute and Emiliem, Inc. Sign Major Translational Medicine and Biomarker Agreement

Strategy directed toward optimal use of novel drug candidates in cancer patients.

See press release

March 29, 2007 - Invitrogen Corporation (IVGN) and Emiliem, Inc. Sign Major Kinase Screening Agreement

CARLSBAD, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced a partnership with Emiliem, Inc. to screen the company’s multi-kinase inhibitors using Invitrogen’s SelectScreen™ platform. Invitrogen will perform biochemical kinase screening, cellular pathway profiling and P450 screening of Emiliem’s compounds targeting cancer. Financial details of the multi-year agreement were not disclosed.

See press release from Invitrogen Corporation

Februrary 20-21, 2007 - Sucha Sudarsanam, CSO, Emiliem, Inc. to present at IBC Life Sciences Partnering and Outsourcing Models in Biology and Pre-clinical R&D in San Diego

January 12, 2007 - Emiliem, Inc. and MIR Preclinical Services sign cancer pharmacology agreement

See press release

December 18, 2006 - Covance Master Service Agreement Signed

Emiliem, Inc. has entered into a Master Services Agreement with Covance, Inc. one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in 20 countries and more than 7500 employees worldwide. Emiliem has agreements with the UK and Germany sites, which provide pre-clinical and clinical capabilities including regulatory filings.

November 27-28, 2006 - DDDS 2006 Drug Discovery and Development Summit: Critical Paths and Approaches for Successful Drug Development

June 12, 2006 - Amie Rodgers joins Emiliem as Research Intern

Amie Rodgers who recently earned a B.S. with Honors at U.C. Berkeley has been appointed to a Research Intern position at Emiliem working under Sucha Sudarsanam, CSO.

May 5, 2006 - GVK Bio Master Service Agreement Signed

Emiliem, Inc. has entered into a Master Services Agreement with GVK Biosciences Private Limited, a leading drug research services company in India. GVK Bio’s parent company is a $1 billion enterprise with interests in infrastructure, services, and manufacturing. GVK Bio has over 1,000 employees, including approximately 500 medicinal chemists, and has laboratories and informatics units located in Hyderabad, India and a knowledge process outsourcing unit in Chennai, India.

April 26, 2006 - Oy Jurilab Master Collaboration Agreement Signed

Emiliem has entered into a Master Collaboration Agreement with Oy Jurilab Ltd, a Finnish corporation founded by members of the Research Institute of Public Health at the University of Kuopio, Finland. Jurilab is applying proprietary discoveries of genes and genetic markers associated with the underlying cause of common diseases and drug response. Jurilab’s current emphasis is on disease risk assessment and molecular sub-typing tests, human-validated drug targets, pharmacogenetic profiling tests, and biochemical and genotyping services. Jurilab combines access to the unique East Finland Founder population with state-of-the-art technologies.

January 3, 2006 - Wilson Sonsini Goodrich & Rosati Agreement

Emiliem, Inc has entered into an agreement with Wilson Sonsini Goodrich & Rosati whereby it will perform patent and general counsel services for the Company.

January 2, 2006 - Emiliem, Inc. Names Management Team

Emiliem, Inc. a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs named its management team today. The Team members have many years of experience in start-ups, biotechnology companies, and big pharma. The team’s background encompasses successful track records in drug research and development, kinase research, toxicology, adverse drug reactions, bioinformatics, biomarker discovery, systems biology, genomics-based research, intellectual property, business operations, business and patent law, finance, accounting, and management.



	HOME \| ABOUT \| CORPORATE \| BUSINESS MODEL\| PIPELINE \| PRESS \| NEWS \| CONTACT

	News Emiliem News and Events January 8, 2010 - Emiliem, Inc. and Jivan Biologics join forces to form JEM Bioscience to discover and commercialize novel molecular diagnostics January, 2010 - Sucha Sudarsanam, CSO & Dale Johnson, CEO Emiliem, Inc. publish Functional Consequences of mTOR Inhibition in Current Opinion Drug Discovery & Development October, 2009 - Dale Johnson, CEO Emiliem, Inc. to present Novel Therapeutics Biologics: Innovative Molecules and Mechanisms - MPI Research Summit Augusta, MI April, 2009 - Dale Johnson, CEO Emiliem, Inc. named to the State of California EPA/DTSC Green Ribbon Science Panel, Sacramento, CA February, 2009 - Dale Johnson, CEO Emiliem, Inc. to present at Cambridge Healthtech Institute 16th International Molecular Medicine Tri-Conference. Shaping Future Medicine San Francisco, CA January, 2009 - Dale Johnson, CEO Emiliem, Inc. and co-authors Subha Srinivasan and Jonathan Bingham publish The ABC'S of Human Alternative Splicing: A Review of ATP-binding Cassette Transporter Splicing in Current Opinion Drug Discovery & Development November, 2008 - Dale Johnson, CEO Emiliem, Inc. to be a panel member at MichBio Biosciences Policy Summit, Novi, MI September, 2008 - Dale Johnson, CEO Emiliem, Inc. to present Novel Approaches for Anti-angiogenic Therapeutics at Dept. of Pharmaceutical Sciences, University of Michigan in Ann Arbor, MI October 16, 2007 - Emiliem Creates R&D Center at Southwest Michigan Innovation Center (See press release) August 28, 2007 - Emiliem and Eidogen-Sertanty Sign Computational Chemistry Master Services Agreement June 11, 2007 - Emiliem and Kalexsyn Sign Medicinal Chemistry Master Services Agreement May 21, 2007 - Emiliem featured as an emerging company in BioCentury, The Bernstein Report on BioBusiness "Emiliem: Not just any kinase". May 3, 2007 - The Van Andel Research Institute and Emiliem, Inc. Sign Major Translational Medicine and Biomarker Agreement Strategy directed toward optimal use of novel drug candidates in cancer patients. See press release March 29, 2007 - Invitrogen Corporation (IVGN) and Emiliem, Inc. Sign Major Kinase Screening Agreement CARLSBAD, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced a partnership with Emiliem, Inc. to screen the company’s multi-kinase inhibitors using Invitrogen’s SelectScreen™ platform. Invitrogen will perform biochemical kinase screening, cellular pathway profiling and P450 screening of Emiliem’s compounds targeting cancer. Financial details of the multi-year agreement were not disclosed. See press release from Invitrogen Corporation Februrary 20-21, 2007 - Sucha Sudarsanam, CSO, Emiliem, Inc. to present at IBC Life Sciences Partnering and Outsourcing Models in Biology and Pre-clinical R&D in San Diego January 12, 2007 - Emiliem, Inc. and MIR Preclinical Services sign cancer pharmacology agreement See press release December 18, 2006 - Covance Master Service Agreement Signed Emiliem, Inc. has entered into a Master Services Agreement with Covance, Inc. one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in 20 countries and more than 7500 employees worldwide. Emiliem has agreements with the UK and Germany sites, which provide pre-clinical and clinical capabilities including regulatory filings. November 27-28, 2006 - DDDS 2006 Drug Discovery and Development Summit: Critical Paths and Approaches for Successful Drug Development June 12, 2006 - Amie Rodgers joins Emiliem as Research Intern Amie Rodgers who recently earned a B.S. with Honors at U.C. Berkeley has been appointed to a Research Intern position at Emiliem working under Sucha Sudarsanam, CSO. May 5, 2006 - GVK Bio Master Service Agreement Signed Emiliem, Inc. has entered into a Master Services Agreement with GVK Biosciences Private Limited, a leading drug research services company in India. GVK Bio’s parent company is a $1 billion enterprise with interests in infrastructure, services, and manufacturing. GVK Bio has over 1,000 employees, including approximately 500 medicinal chemists, and has laboratories and informatics units located in Hyderabad, India and a knowledge process outsourcing unit in Chennai, India. April 26, 2006 - Oy Jurilab Master Collaboration Agreement Signed Emiliem has entered into a Master Collaboration Agreement with Oy Jurilab Ltd, a Finnish corporation founded by members of the Research Institute of Public Health at the University of Kuopio, Finland. Jurilab is applying proprietary discoveries of genes and genetic markers associated with the underlying cause of common diseases and drug response. Jurilab’s current emphasis is on disease risk assessment and molecular sub-typing tests, human-validated drug targets, pharmacogenetic profiling tests, and biochemical and genotyping services. Jurilab combines access to the unique East Finland Founder population with state-of-the-art technologies. January 3, 2006 - Wilson Sonsini Goodrich & Rosati Agreement Emiliem, Inc has entered into an agreement with Wilson Sonsini Goodrich & Rosati whereby it will perform patent and general counsel services for the Company. January 2, 2006 - Emiliem, Inc. Names Management Team Emiliem, Inc. a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs named its management team today. The Team members have many years of experience in start-ups, biotechnology companies, and big pharma. The team’s background encompasses successful track records in drug research and development, kinase research, toxicology, adverse drug reactions, bioinformatics, biomarker discovery, systems biology, genomics-based research, intellectual property, business operations, business and patent law, finance, accounting, and management.